A 20‐year follow‐up of the mesh wallstent in the treatment of detrusor external sphincter dyssynergia in patients with spinal cord injury

• Published in: BJU international 2010-11, Vol.106 (10), p.1510-1513
• Main Authors: Abdul‐Rahman, Ahmad, Ismail, Soran, Hamid, Rizwan, Shah, Julian
• Format: Article
• Language: English
• Subjects: Adult; Aged; Ataxia - etiology; Ataxia - physiopathology; Ataxia - surgery; Biological and medical sciences; Cerebrospinal fluid. Meninges. Spinal cord; detrusor sphincter dyssynergia; Follow-Up Studies; Humans; Male; Medical sciences; Middle Aged; Nephrology. Urinary tract diseases; Nervous system (semeiology, syndromes); Neurology; Quadriplegia - complications; Retrospective Studies; sphincter; Spinal Cord Injuries - complications; Spinal Cord Injuries - physiopathology; Spinal cord injury; Stents; Treatment Outcome; urethral stent; Urinary Bladder Diseases - etiology; Urinary Bladder Diseases - physiopathology; Urinary Bladder Diseases - surgery; Urinary system involvement in other diseases. Miscellaneous; Urinary tract. Prostate gland; Urodynamics - physiology
• ISSN: 1464-4096; 1464-410X
• DOI: 10.1111/j.1464-410X.2010.09379.x

Study Type – Therapy (case series)
Level of Evidence 4 OBJECTIVE To assess the long‐term (20 years) effectiveness of the UroLume wallstentTM (Pfizer Inc., UK) in the treatment of detrusor external sphincter dyssynergia (DESD) in patients with spinal cord injury (SCI). PATIENTS AND METHODS Twelve patients with quadriplegia secondary to SCI underwent external striated sphincter stenting with the UroLume wallstent in place of sphincterotomy for DESD ≈ 20 years ago. The mean (range) age was 41.8 (26–65) years. Eleven patients had cervical level injury whilst one had a thoracic injury. All the patients were shown to have high‐pressure neurogenic detrusor overactivity and DESD with incomplete emptying on preoperative video‐cystometrograms (VCMG). RESULTS Six of the 12 patients have now been followed‐up for a mean (range) of 20 (19–21) years. Of the remaining six, two were lost to follow‐up at 1 and 3 years, but both remained free of complications during that time. Two patients developed encrustation causing obstruction, requiring stent removal within 1 year of insertion. Another patient with an adequately functioning stent died 7 years after stent insertion from a chest infection. The twelfth patient developed bladder cancer 14 years after stent insertion and underwent cystectomy with urinary diversion. VCMG follow‐up of the six patients showed a significantly sustained reduction of maximum detrusor pressure and duration of detrusor contraction at the 20‐year follow‐up. Five of these six patients developed bladder neck dyssynergia of varying degrees as shown on VCMG within the first 9 years of follow‐up. All were successfully treated with bladder neck incision (BNI) where the last BNI needed was at 12 years. We did not encounter any problem with stent migration, urethral erosion, erectile dysfunction or autonomic dysreflexia. CONCLUSION Urethral stenting using the UroLume wallstent is effective in the management of DESD in patients with SCI and provides an acceptable long‐term (20‐year follow‐up) alternative to sphincterotomy. The failures manifest within the first few years and can be managed easily with stent removal without any significant problems. Bladder neck dyssynergia was the long‐term complication which was treated successfully with BNI. It has no significant interference with erectile function, being reversible, minimally invasive and has a shorter hospital stay.